Adding a cheap, older chemotherapy drug to the treatment for men with advanced prostate cancer can help them live longer without making them significantly sicker, researchers reported on Sunday.
It’s a surprising reversal of the latest common wisdom, which is that less treatment is often better for cancer patients.
The extra upfront treatment improved survival by 39 percent in the men in the study, whose prostate cancer had spread to their bones or elsewhere – patients who often have little hope.
“This is one of the biggest improvements in survival we have seen in patients with adult solid metastatic tumors,” said Dr. Christopher Sweeney of the Dana-Farber Cancer Institute in Boston, who helped lead the study.
A common treatment for men whose prostate cancer has spread is called androgen suppression or chemical castration – drugs are used to cut production of testosterone, which feeds the tumor. Sometimes the cancer keeps growing, anyway, and the question has been when to add more chemotherapy.
Doctors are reluctant to do too much too soon, because chemo can be toxic. “Do you throw everything at the patient in the beginning or do you wait?” asked Dr. Clifford Hudis, president of the American Society for Clinical Oncology, which highlighted the findings at its annual meeting.
Sweeney’s government-funded team studied 790 men who got either chemical castration alone or with the drug docetaxel, sold under the brand name Taxotere but also available as a cheaper generic version.
After two and a half years, 136 men who got hormone treatment alone had died, compared to 101 men who got both drugs.
“This study shows a remarkable and meaningful prolongation in survival for advanced prostate cancer,” Hudis said.
More than 240,000 men are diagnosed with prostate cancer in a year and close to 30,000 die from it.
“This will engender controversy because the chemo drug is not without controversy,” Hudis told NBC News. “They are talking about survival. They are not just talking about disease control.”
One of the men who got docetaxel died because of side effects of the treatment, but for the most part the extra drug did not make the patients sicker. Sweeney pointed out it’s important for doctors to make sure men are healthy enough to stand it.
“Some patients are too frail for chemotherapy,” Sweeney told a news conference. “It is a little difficult for an 80-year-old to get chemotherapy.”
Hudis, who is also an oncologist at the Memorial Sloan-Kettering Cancer Center, said the findings were only possible because of government-funded cancer research. “These are often studies that industry is less interested in performing, for example finding a new use for an old drug,” he said.
First published June 1 2014, 4:56 AM
Maggie Fox
Maggie Fox is senior health writer for NBCNews.com and TODAY.com, writing top news on health policy, medical treatments and disease.
She's a former managing editor for healthcare and technology at National Journal and global health and science editor for Reuters based in Washington, D.C. and London.
She's reported for news agencies, radio, newspapers, magazines and television from across Asia, the Middle East, Africa and Europe covering news ranging from war to politics and, of course, health and science. Her reporting has taken Maggie to Lebanon, Syria and Libya; to China, South Korea, Thailand, the Philippines and Pakistan; to Bosnia, Croatia and Serbia and to Ireland and Northern Ireland and across the rest of Europe.
Maggie has won awards from the Society of Business Editors and Writers, the National Immunization Program, the Overseas Press Club and other organizations. She's done fellowships at Harvard Medical School, the National Institutes of Health and the University of Maryland.
... Expand Bio
It’s a surprising reversal of the latest common wisdom, which is that less treatment is often better for cancer patients.
The extra upfront treatment improved survival by 39 percent in the men in the study, whose prostate cancer had spread to their bones or elsewhere – patients who often have little hope.
“This is one of the biggest improvements in survival we have seen in patients with adult solid metastatic tumors,” said Dr. Christopher Sweeney of the Dana-Farber Cancer Institute in Boston, who helped lead the study.
A common treatment for men whose prostate cancer has spread is called androgen suppression or chemical castration – drugs are used to cut production of testosterone, which feeds the tumor. Sometimes the cancer keeps growing, anyway, and the question has been when to add more chemotherapy.
Doctors are reluctant to do too much too soon, because chemo can be toxic. “Do you throw everything at the patient in the beginning or do you wait?” asked Dr. Clifford Hudis, president of the American Society for Clinical Oncology, which highlighted the findings at its annual meeting.
Sweeney’s government-funded team studied 790 men who got either chemical castration alone or with the drug docetaxel, sold under the brand name Taxotere but also available as a cheaper generic version.
After two and a half years, 136 men who got hormone treatment alone had died, compared to 101 men who got both drugs.
“This study shows a remarkable and meaningful prolongation in survival for advanced prostate cancer,” Hudis said.
More than 240,000 men are diagnosed with prostate cancer in a year and close to 30,000 die from it.
“This will engender controversy because the chemo drug is not without controversy,” Hudis told NBC News. “They are talking about survival. They are not just talking about disease control.”
One of the men who got docetaxel died because of side effects of the treatment, but for the most part the extra drug did not make the patients sicker. Sweeney pointed out it’s important for doctors to make sure men are healthy enough to stand it.
“Some patients are too frail for chemotherapy,” Sweeney told a news conference. “It is a little difficult for an 80-year-old to get chemotherapy.”
Hudis, who is also an oncologist at the Memorial Sloan-Kettering Cancer Center, said the findings were only possible because of government-funded cancer research. “These are often studies that industry is less interested in performing, for example finding a new use for an old drug,” he said.
First published June 1 2014, 4:56 AM
Maggie Fox is senior health writer for NBCNews.com and TODAY.com, writing top news on health policy, medical treatments and disease.
She's a former managing editor for healthcare and technology at National Journal and global health and science editor for Reuters based in Washington, D.C. and London.
She's reported for news agencies, radio, newspapers, magazines and television from across Asia, the Middle East, Africa and Europe covering news ranging from war to politics and, of course, health and science. Her reporting has taken Maggie to Lebanon, Syria and Libya; to China, South Korea, Thailand, the Philippines and Pakistan; to Bosnia, Croatia and Serbia and to Ireland and Northern Ireland and across the rest of Europe.
Maggie has won awards from the Society of Business Editors and Writers, the National Immunization Program, the Overseas Press Club and other organizations. She's done fellowships at Harvard Medical School, the National Institutes of Health and the University of Maryland.
... Expand Bio
via Smart Health Shop Forum http://ift.tt/1kxhkD5
No comments:
Post a Comment